Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded pharmaceutical products, signed a lease
for new corporate headquarters at 10 North Park Place in Morristown, New Jersey
“Establishing Pernix’s headquarters in Morristown, New Jersey continues our efforts to build Pernix into a focused specialty pharmaceutical company with an experienced management team that is well-positioned for additional product acquisitions,” Doug Drysdale, President/CEO of Pernix said.
According to the firm, its new corporate headquarters
will be occupied in mid-May “and is a key step towards the achievement of several corporate initiatives, including improving the efficiency of the Company’s operational infrastructure by consolidating office locations and hiring and retaining experienced employees.”
“ The Company has shifted its emphasis from horizontal integration to focusing on its core sales and marketing strengths to build a leading specialty pharmaceutical
business,” company officials said.
The Company markets a portfolio of branded products, including: CEDAX, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO, REZIRA and VITUZ. The Company also markets SILENOR, a non-narcotic product for the treatment of insomnia and KHEDEZLA, a treatment for major depressive disorder.